| Comprehensive molecular characterization of papillary renal-cell carcinoma CGAR Network New England Journal of Medicine 374 (2), 135-145, 2016 | 1269 | 2016 |
| The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma CJ Ricketts, AA De Cubas, H Fan, CC Smith, M Lang, E Reznik, R Bowlby, ... Cell reports 23 (1), 313-326. e5, 2018 | 922 | 2018 |
| The long tail of oncogenic drivers in prostate cancer J Armenia, SAM Wankowicz, D Liu, J Gao, R Kundra, E Reznik, ... Nature genetics 50 (5), 645-651, 2018 | 829 | 2018 |
| Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, ... Cell 173 (3), 581-594. e12, 2018 | 781 | 2018 |
| An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma AA Hakimi*, E Reznik*, CH Lee, CJ Creighton, AR Brannon, A Luna, ... Cancer Cell 29 (1), 104-116, 2016 | 715 | 2016 |
| Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles F Farshidfar, S Zheng, MC Gingras, Y Newton, J Shih, AG Robertson, ... Cell reports 18 (11), 2780-2794, 2017 | 714 | 2017 |
| Mitochondrial DNA copy number variation across human cancers E Reznik, ML Miller, Y Şenbabaoğlu, N Riaz, J Sarungbam, SK Tickoo, ... elife 5, e10769, 2016 | 485 | 2016 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 433 | 2022 |
| Multilevel genomics-based taxonomy of renal cell carcinoma F Chen, Y Zhang, Y Şenbabaoğlu, G Ciriello, L Yang, E Reznik, B Shuch, ... Cell reports 14 (10), 2476-2489, 2016 | 363 | 2016 |
| Pathway thermodynamics highlights kinetic obstacles in central metabolism E Noor, A Bar-Even, A Flamholz, E Reznik, W Liebermeister, R Milo PLoS computational biology 10 (2), e1003483, 2014 | 351 | 2014 |
| Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ... Science 366 (6466), 714-723, 2019 | 264 | 2019 |
| Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes I Ganly, V Makarov, S Deraje, YY Dong, E Reznik, V Seshan, ... Cancer cell 34 (2), 256-270. e5, 2018 | 264 | 2018 |
| Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs K Hadi, X Yao, JM Behr, A Deshpande, C Xanthopoulakis, H Tian, ... Cell 183 (1), 197-210. e32, 2020 | 213 | 2020 |
| Unifying cancer and normal RNA sequencing data from different sources Q Wang, J Armenia, C Zhang, AV Penson, E Reznik, L Zhang, T Minet, ... Scientific data 5 (1), 1-8, 2018 | 197 | 2018 |
| Graph curvature for differentiating cancer networks R Sandhu, T Georgiou, E Reznik, L Zhu, I Kolesov, Y Senbabaoglu, ... Scientific reports 5 (1), 12323, 2015 | 185 | 2015 |
| Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition JJ Harding, MA Lowery, AH Shih, JM Schvartzman, S Hou, C Famulare, ... Cancer discovery 8 (12), 1540-1547, 2018 | 182 | 2018 |
| A Landscape of Metabolic Variation across Tumor Types E Reznik, A Luna, BA Aksoy, EM Liu, K La, I Ostrovnaya, CJ Creighton, ... Cell Systems 6 (3), 301-313. e3, 2018 | 157 | 2018 |
| Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates CH Lee, MH Voss, MI Carlo, YB Chen, M Zucker, A Knezevic, ... Journal of Clinical Oncology 40 (21), 2333-2341, 2022 | 141 | 2022 |
| Hyperpolarized MRI of human prostate cancer reveals increased lactate with tumor grade driven by monocarboxylate transporter 1 KL Granlund, SS Tee, HA Vargas, SK Lyashchenko, E Reznik, S Fine, ... Cell metabolism 31 (1), 105-114. e3, 2020 | 137 | 2020 |
| Mitochondrial respiratory gene expression is suppressed in many cancers ED Reznik, Q Wang, K La, N Schultz, C Sander Elife 6, e21592, 2017 | 129 | 2017 |
Chris SanderHarvard Medical School, Broad Institute, MGH, Dana-Farber Cancer Institute, Memorial Sloan KetteringVerified email at sanderlab.org